Evidence map›Paper›PMID 36321714›Full record

ReviewJournal of cardiac surgery2022

Failing Fontan cardiovascular support: Review.

Joseph B Zwischenberger, Katherine A Breetz, Cherry Ballard-Croft, Dongfang Wang

Open access · greenAbstract readReview
In one paragraph

Review in Journal of cardiac surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The fate of the Fontan circulation.European heart journal supplements : journal of the European Society of Cardiology · 2026
    Article
  3. Long-term survival and complications of Fontan patients: where do we stand?American journal of cardiovascular disease · 2026
    Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Joseph B ZwischenbergerDivision of Cardiothoracic Surgery, University of Kentucky, Lexington, Kentucky, USA.ORCID http://orcid.org/0000-0001-6812-2571
Katherine A BreetzCollege of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Cherry Ballard-CroftDivision of Surgical Research, Department of Surgery, University of Kentucky, Lexington, Kentucky, USA.ORCID http://orcid.org/0000-0003-3639-7049
Dongfang WangDivision of Surgical Research, Department of Surgery, University of Kentucky, Lexington, Kentucky, USA.
University of Kentucky · US

Funding

Development of Percutaneous DLC for Total Cavo-pulmonary AssistanceR44HL129490 · NHLBI · W-Z BIOTECH, LLC · PI TOPAZ, STEPHEN R · 2016 to 2017
$1.0M
NHLBI NIH HHS R44 HL129490NIH HHS
6 · The paper itself

Abstract

backgroundAlthough all congenital heart defects (CHD) present unique challenges, univentricular CHD are especially challenging given the difficulty of passively perfusing pulmonary blood flow. Three surgical procedures are required within the first years of life, with the final completing a Fontan circulation in which the inferior vena cava is connected to the pulmonary artery and previously connected superior vena cava. This allows passive venous return to the pulmonary circulation then flow into the single ventricle for systemic circulation.

methodsAlthough a Fontan provides successful palliation for two to three decades, many complications can arise as pulmonary resistance must remain low to allow adequate forward flow. Eventually, the failing Fontan circulation requires temporary support as the patient awaits a heart transplant. We reviewed PubMed, Google Scholar, and U. Kentucky library for different techniques evaluated to support a failing Fontan circulation.

resultsMultiple technologies have been developed as a bridge to transplant to decrease morbidity. Innovative types of extracorporeal membrane oxygenation, ventricular assist devices, and total artificial hearts have been attempted in laboratory settings as well as in Fontan patients with varying degrees of success. This article emphasizes the strengths and weaknesses of each technology in the context of Fontan physiology.

conclusionThe end game for these patients remains a heart transplant. Without easy access to donors, each of the options discussed is a potential bridge to limit morbidity and mortality until a suitable donor heart becomes available.

Indexed as

Fontan ProcedureHeart-Assist DevicesHeart Defects, CongenitalHeart TransplantationHemodynamicsHumansPulmonary ArteryTissue DonorsVena Cava, Superiorcongenital heart defects (CHD)extracorporeal membrane oxygenation (ECMO)Fontan circulationtotal artificial heart (TAH)ventricular assist devices (VAD)

Identifiers

PMID36321714
PMCPMC9812883
OpenAlexW4307969022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.